- 米国企業
- IONIS PHARMACEUTICALS INC
IONIS PHARMACEUTICALS INCIONS
| 2010年
12月31日 | 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA.. | - | - | - | - | - | - | - | - | 255 | 352 | 365 | 342 | 303 | 309 |
|---|
| Royalty revenues from the sale of SPINRAZA (nusinersen). | - | - | - | - | - | - | - | - | - | - | 287 | 268 | 242 | 240 |
|---|
| TEGSEDI and WAYLIVRA Revenue, Net | - | - | - | - | - | - | - | - | 2 | 42 | 70 | 56 | 30 | 35 |
|---|
| Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA. | - | - | - | - | - | - | - | - | - | - | - | - | - | 68 |
|---|
| Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA. | - | - | - | - | - | - | - | - | 15 | 17 | 11 | 19 | 31 | 33 |
|---|
| Revenue from research and development services. | - | - | - | - | - | - | - | - | - | - | - | - | 284 | 479 |
|---|
| Revenue from research and development services performed under a collaborative agreement. | - | - | - | - | - | - | - | - | - | - | - | - | 207 | 353 |
|---|
| Joint development revenue for eplontersen. | - | - | - | - | - | - | - | - | - | - | - | - | 77 | - |
|---|
| Joint development revenue for WAINUA (eplontersen). | - | - | - | - | - | - | - | - | - | - | - | - | - | 126 |
|---|
| Revenue | 108 | 99 | 102 | 147 | 214 | 284 | 347 | 508 | 600 | 1,123 | 729 | 810 | 587 | 788 |
|---|
| Revenue from the sale of medicines commercially as well as licensing and royalty revenues from other medicines, including SPINRAZA.. | - | - | - | - | - | - | - | - | 255 | 352 | 365 | 342 | 303 | 309 |
|---|
| Royalty revenues from the sale of SPINRAZA (nusinersen). | - | - | - | - | - | - | - | - | - | - | 287 | 268 | 242 | 240 |
|---|
| TEGSEDI and WAYLIVRA Revenue, Net | - | - | - | - | - | - | - | - | 2 | 42 | 70 | 56 | 30 | 35 |
|---|
| Revenue from the sale of other medicines commercially as well as licensing and royalty revenue from other medicines, including TEGSEDI and WAYLIVRA. | - | - | - | - | - | - | - | - | - | - | - | - | - | 68 |
|---|
| Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA. | - | - | - | - | - | - | - | - | 15 | 17 | 11 | 19 | 31 | 33 |
|---|
| Revenue from research and development services. | - | - | - | - | - | - | - | - | - | - | - | - | 284 | 479 |
|---|
| Revenue from research and development services performed under a collaborative agreement. | - | - | - | - | - | - | - | - | - | - | - | - | 207 | 353 |
|---|
| Joint development revenue for eplontersen. | - | - | - | - | - | - | - | - | - | - | - | - | 77 | - |
|---|
| Joint development revenue for WAINUA (eplontersen). | - | - | - | - | - | - | - | - | - | - | - | - | - | 126 |
|---|
| Revenue | 108 | 99 | 102 | 147 | 214 | 284 | 347 | 508 | 600 | 1,123 | 729 | 810 | 587 | 788 |
|---|
| Cost of sales | - | - | - | - | - | - | - | - | 2 | 4 | 12 | 11 | 14 | 9 |
|---|
| The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense. | - | - | - | - | - | 322 | 344 | 375 | 415 | 466 | 535 | 643 | 833 | 900 |
|---|
| Selling, general and administrative | - | - | - | - | - | - | - | 108 | 245 | 287 | 354 | 186 | 150 | 233 |
|---|
| Total operating expenses | - | - | - | - | - | - | - | - | - | 757 | 901 | 841 | 998 | 1,141 |
|---|
| Loss from operations | -48 | -71 | -69 | -52 | -48 | -76 | -46 | 25 | -61 | 366 | -172 | -30 | -410 | -354 |
|---|
| Investment income | 3 | 2 | 2 | 2 | 3 | 4 | 5 | 8 | 30 | 52 | 31 | 10 | 25 | 89 |
|---|
| Interest expense | 13 | 17 | 21 | 19 | 22 | 37 | 39 | 45 | 45 | 49 | 45 | 9 | 8 | 13 |
|---|
| Gain (loss) on investments | -1 | 4 | 1 | 2 | 1 | - | - | - | - | - | 17 | 10 | -7 | -2 |
|---|
| Amount of interest expense using the effective interest rate method and amortization of issuance costs related to the sale of future royalties. | - | - | - | - | - | - | - | - | - | - | - | - | - | 69 |
|---|
| Gain (loss) on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 |
|---|
| Gain (loss) on investments | -1 | 4 | 1 | 2 | 1 | - | - | - | - | - | 17 | 10 | -7 | -2 |
|---|
| Other expenses | - | - | - | - | - | - | - | - | -0 | -1 | -0 | -1 | -7 | 14 |
|---|
| Gain (loss) on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 |
|---|
| Other expenses | - | - | - | - | - | - | - | - | -0 | -1 | -0 | -1 | -7 | 14 |
|---|
| Loss before income tax benefit (expense) | - | -85 | -75 | -67 | -54 | -88 | -84 | -23 | -76 | 347 | -170 | -29 | -258 | -334 |
|---|
| Total income tax expense (benefit) | 0 | 0 | - | - | -15 | 0 | 3 | -6 | -291 | 44 | 317 | -1 | 12 | 32 |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | - | - | -17 | 215 | 303 | -487 | -29 | -270 | - |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | -88 | -87 | -6 | 274 | 303 | -451 | -29 | -270 | -366 |
|---|
| Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc. | - | - | - | - | - | - | - | -11 | -59 | 9 | -35 | - | - | - |
|---|
| Basic net loss per share (in dollars per share) | -0.62 | -0.85 | - | - | - | - | - | 0.08 | 2.09 | 2.12 | -3.23 | -0.2 | -1.9 | -2.56 |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | -88 | -87 | -6 | 274 | 303 | -451 | -29 | -270 | -366 |
|---|
| Basic net loss per share (in dollars per share) | -0.62 | -0.85 | - | - | - | - | - | 0.08 | 2.09 | 2.12 | -3.23 | -0.2 | -1.9 | -2.56 |
|---|
| Diluted net loss per share (in dollars per share) | -0.62 | -0.85 | - | - | - | - | - | 0.08 | 2.07 | 2.08 | -3.23 | -0.2 | -1.9 | -2.56 |
|---|
| Diluted net loss per share (in dollars per share) | -0.62 | -0.85 | - | - | - | - | - | 0.08 | 2.07 | 2.08 | -3.23 | -0.2 | -1.9 | -2.56 |
|---|